ZhiRan Medical Named to Rongzhong's '2025-2026 China Future Unicorn Top 50' List

May 28, 2026 17:50 CST Updated 17:50

BCIFlex

Invasive High-Throughput Ultra-Thin Flexible Brain-Computer Interface System Developer

Recently, Rongzhong officially released the "2025-2026 China Power 50 Enterprise List", a portfolio company of Danlu Capital“BCIFlex”By virtue of its solid innovation capabilities and high growth potential, it ranked on“Top 50 Future Unicorn Enterprises in China” List.

The release of this ranking coincides with a historic window as China’s economy transitions from scale-driven to innovation-driven growth, while national strategies channel unprecedented support into emerging and future industries. Six major strategic directions, including quantum technology, bio-manufacturing, and brain-computer interfaces, have been explicitly incorporated into the top-level design, ushering in broader prospects for the deep integration of healthcare and cutting-edge technologies. The Rongzhong Power50 List precisely highlights the benchmark forces demonstrating the strongest innovative resilience along this evolutionary trajectory.

Leveraging its proprietary database and multi-dimensional cross-verification, Rongzhong Research has constructed a quantifiable growth value assessment model centered on four core dimensions: comprehensive strength, innovation capability, financing strength, and social evaluation. Through this framework, it has precisely identified 150 outstanding enterprises in China's current new economy sector. This ranking not only summarizes the achievements of industrial development, but also serves as a multidimensional map of China's innovation landscape and a crucial reference for forecasting future trends.

@RongzhongFinance

BCIFlex's inclusion in the "Future Unicorn" list serves as a strong industry endorsement of its technological barriers, commercialization capabilities, and long-term development value. As an enterprise deeply committed to healthcare innovation, BCIFlex is steadily forging ahead amidst the wave of industry transformation, backed by robust R&D and a clear industrial development roadmap.

Danlu Perspectives

As an early-stage investor and steadfast partner to BCIFlex, Danlu Capital has consistently focused on early-stage and innovative investments in the healthcare sector. We are honored to have witnessed and accompanied a team that combines robust technical expertise with ambitious growth potential as it continually achieves new breakthroughs. This honor further reinforces our conviction that:In the face of true innovation, time is the best friend, and companionship is the most enduring testament of commitment.

Congratulations once again to BCIFlex. Moving forward, Danlu Capital will continue to uphold professionalism and humility, deepening our focus on early-stage healthcare investments. Together with more entrepreneurs, we will transform innovative laboratory concepts into life-changing products and services, contributing enduring and substantial strength to the Healthy China initiative.

About BCIFlex

Founded in 2022, Beijing Bciflex Medical Technology Co., Ltd. is a hard-tech innovation enterprise dedicated to the research and development of invasive flexible brain-computer interface platforms.

Beijing Bciflex Medical Technology Co., Ltd. was co-founded by brain-computer interface scientist Dr. Fang Ying and serial entrepreneur Dr. Song Qi. Dr. Fang serves as the lead for the brain science special project under the Ministry of Science and Technology, while Dr. Song previously spearheaded the clinical registration for the first Class III medical device certification for AI healthcare in China. BCIFlex independently developed stretchable flexible electrodes and a 1,000-channel implantable signal acquisition system, successfully overcoming the long-standing industry challenge of electrode disconnection. The related findings were published in the top-tier international journal *Nature Electronics*. The company has secured cumulative financing of nearly 800 million RMB, backed by prominent investors including Legend Capital, IDG Capital, and Sequoia China. In May 2026, BCIFlex initiated the first GCP multi-center clinical trial in China for an invasive brain-computer interface system with over 100 channels (the LEAP study) at Beijing Tiantan Hospital, marking the official entry of China's high-channel-count invasive BCI technology into the clinical translation phase.

Note: Some content and images in this article are sourced from the internet. If any copyright infringement occurs, please notify us for removal.

Data and image source: WeChat Official Account @Rongzhong Finance

`Danlu Capital`